Last Updated : December 20, 2024
Details
FilesGeneric Name:
semaglutide
Project Status:
Active
Therapeutic Area:
Weight management
Manufacturer:
Novo Nordisk Canada Inc.
Call for patient/clinician input open:
Brand Name:
Wegovy
Project Line:
Reimbursement Review
Project Number:
SR0841-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
As an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of equal to or greater than 27 kg/m2 and established cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease).
Submission Type:
Resubmission
Fee Schedule:
Schedule A
Indications:
Wegovy (semaglutide injection) is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: • 30 kg/m2 or greater (obesity), or• 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, dyslipidemia, or obstructive sleep apnea.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | October 17, 2024 |
|---|---|
| Call for patient/clinician input closed | December 06, 2024 |
| Submission received | November 27, 2024 |
| Submission accepted | December 11, 2024 |
| Review initiated | December 12, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | March 06, 2025 |
| Deadline for sponsors comments | March 18, 2025 |
| CADTH review report(s) and responses to comments provided to sponsor | April 09, 2025 |
| Expert committee meeting (initial) | April 23, 2025 |
| Draft recommendation issued to sponsor | May 05, 2025 To May 07, 2025 |
| Draft recommendation posted for stakeholder feedback | May 15, 2025 |
| End of feedback period | May 30, 2025 |
Files
Last Updated : December 20, 2024